摘要
目的探讨参麦注射剂联合低分子肝素对血液高凝状态的晚期肺癌患者的影响。方法自2016年1月至2017年1月,前瞻性收集收治的血液高凝的晚期肺癌患者92例,将患者随机分为观察组和对照组(各46例)。在常规化疗的基础上,观察组给予参麦注射剂联合低分子肝素治疗,对照组仅给予低分子肝素治疗。观察2组患者凝血指标、生活质量、临床疗效、并发症和免疫功能。结果 2组患者治疗前纤维蛋白原、D-二聚体、健康相关的生存质量(SF-36)、深静脉血栓、CD4^+T细胞、CD8^+T细胞和CD4^+/CD8^+等比较差异均无统计学意义(P>0.05),但治疗后与对照组比较,观察组患者纤维蛋白原显著降低[(2.22±1.04)vs(3.07±1.02)mg·L^(-1),P<0.01];D-二聚体显著降低[(1.26±0.67)vs(1.99±0.68)mg·L^(-1),P<0.01];健康相关的生存质量(SF-36)显著增高(68.65±9.04 vs 58.81±8.88,P<0.01);深静脉血栓发生率显著降低(23.91%vs 6.52%,P<0.05);CD4^+T细胞比例显著升高[(45.91±3.62)vs(37.42±3.21)%,P<0.01];CD8^+T细胞比例显著降低[(24.56±2.89)vs(32.37±2.46)%,P<0.01];CD4^+/CD8^+显著升高(1.57±0.25 vs 1.21±0.15,P<0.01)。2组患者临床疗效、血小板计数和其余并发症比较差异均无统计学意义(P>0.05)。结论参麦注射剂联合低分子肝素可以有效改善晚期肺癌患者凝血功能,防治血栓形成,改善患者生存质量。
AIM To investigate the effect of Shenmai injection combined with low molecular weight heparin （LMWH） on advanced lung cancer patients with hypercoagulation. METHODS Totally 92 patients with ad- vanced lung cancer and hypercoagulation were prospectively collected in our hospital from January 2016 to January 2017. The patients were randomly divided into observation group and control group （46 cases in each group）. On the basis of conventional chemotherapy, the observation group was given Shenmai injection combined with low mo- lecular weight heparin treatment, while the control group was only treated with low molecular heparin treatment. The coagulation parameters, quality of life, clinical efficacy , complications and immune function were observed in the 2 groups. RESULTS There were no significant differences in fibrinogen, D-dimer, health related quality of life （SF-36） , deep-vein thrombosis, CD4^＋T cell, CD8^＋T cell and CD4^＋/CD8^＋ between the 2 groups before treatment （ P 〉 0.05 ）. However, when compared with the control group after treatment, patients in the observation group got a significant decreases in fibrinogen [ （2.22 ± 1.04 ） vs （ 3.07 ± 1.02） mg·L^-1, P 〈 0.01 ], a significant decreases in D-dimer [ （ 1.26 ± 0.67 ） vs （ 1.99± 0.68 ） mg·L^-1 , P 〈 0.01 ] , a significant elevation in health related quality of life （ SF-36 ） （68.65 ±9.04 vs 58.81± 8.88, P 〈 0.01 ）, a significant lower rate of deep- vein thrombosis （23.91% vs 6.52%, P 〈0.05）, a significant elevation in CD4^＋T cell [ （45.91± 3.62） vs （37.42 ±3.21）% , P 〈0.01] , a significant decrease in CD8^＋T cell [（24.56±2.89） vs （32.37±2.46）%, P 〈 0.01 ] and a significant increase in CD4^＋/CD8^＋（1.57± 0.25 vs 1.21±0.15, P 〈 0.01 ）. There was no sig- nificant differences between the 2 groups in clinical efficacy, platelet count and other complications between the 2 groups （P 〉 0. 05）. CONCLUSION Shenmai injection combined with low molecular weight heparin can effectively improve coagulation function, prevent thrombosis and improve the quality of life of advanced lung cancer patients.
作者
张刘海
吕群
ZHANG Liuhai;LYU Qun(Department of Pulmonary Medicine, The Affiliated Hospital of Hangzhou Normal Uni- versity , Hangzhou 310015, China)
出处
《中国临床药学杂志》
CAS
2018年第2期95-98,共4页
Chinese Journal of Clinical Pharmacy
基金
浙江省医学会临床科研基金(编号2015ZYC-A36)
关键词
血栓形成
晚期肺癌
参麦注射剂
低分子肝素
thrombosis
advanced lung cancer
Shenmai injection
low molecular weight heparin
作者简介
张刘海（1990-），男。研究方向：肺癌。E—mail：zhangliuhai108@163．com;【通信作者】吕群（1967-），女，主任医师。研究方向：肺癌。E-mail：zhangliuhai108@163．com
